aBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana;
bDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA;
cBennett Statistical Consulting, Inc., Ballston Lake, NY;
dDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA;
eUniversity of California, San Diego, La Jolla, CA;
fNational Institutes of Health, Bethesda, MD;
gBrigham and Women's Hospital, Boston, MA; and
hRagon Institute of MGH, MIT, and Harvard, Cambridge, MA
Correspondence to: Gbolahan Ajibola, MBBS, Botswana Harvard AIDS Institute, Plot 1836, North Ring Road, Gaborone, Botswana (e-mail: [email protected].
Funding for the Early Infant Treatment study was provided by the National Institute of Allergy and Infectious Diseases (U01 AI114235).
The authors have no conflicts of interest to disclose.
Trial Registration: Clinicaltrials.gov, NCT02369406, https://clinicaltrials.gov/
G.A., K.M. equal contribution.
